Table 3 Norepinephrine and opioid analyses
Isoflurane (n = 23) | Xenon (n = 23) | P-value | |
|---|---|---|---|
Norepinephrine consumption | |||
Pre-existent arterial hypertension, n (%) | 12 (52) | 12 (52) | – |
Total amount per group, μg | 9945.5 | 934.5 | – |
- with pre-existent hypertension | 7785.5 | 644.5 | – |
- without pre-existent hypertension | 2160.0 | 290.0 | – |
Cumulative intraoperative consumption, median (IQR), μg | 195.0 [17.5–538.5] | 0 [0–42.5] | 0.001** |
- with pre-existent hypertension | 422.8 [25.0–1415.5] | 15 [0–77.5] | 0.006** |
- without pre-existent hypertension | 20.0 [5.0–275.0] | 0 [0–5.0] | 0.040* |
Duration of norepinephrine administration, median (IQR), min | 95.0 [10–192.5] | 0 [0–30.0] | 0.002** |
- with pre-existent hypertension | 167.5 [15.0–260.0] | 10.0 [0–42.5] | 0.008** |
- without pre-existent hypertension | 20.0 [2.5–120.0] | 0 [0–5.0] | 0.065 |
Proportion of the study treatment duration represented by the norepinephrine administration duration, median (IQR), % | 57.1 [6.2–91.7] | 0 [0–13.2] | 0.001** |
- with pre-existent hypertension | 68.6 [9.4–93.3] | 6.7 [0–26.1] | 0.008** |
- without pre-existent hypertension | 15.0 [1.0–88.0] | 0 [0–2.6] | 0.034* |
Opioid (sufentanil) consumption | |||
Total intraoperative consumption per group, μg | 905 | 1005 | |
Additional epidural anaesthesia, n (%) | 15 (66) | 19 (83) | |
Cumulative intraoperative consumption, median (IQR), μg | 40.0 [30.0–50.0] | 30.0 [25.0–55.0] | 0.912 |
- with epidural anaesthesia | 30.0 [25.0–47.5] | 30.0 [25.0–45.0] | 0.891 |
- without epidural anaesthesia | 47.5 [40.0–55.0] | 62.5 [50.0–82.5] | 0.109 |